Sign In  |  Register  |  About Los Altos  |  Contact Us

Los Altos, CA
September 01, 2020 1:26pm
7-Day Forecast | Traffic

  • Search Hotels in Los Altos

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Qiagen N.V. (NY: QGEN )

43.75 +0.51 (+1.18%)
Official Closing Price Updated: 7:00 PM EST, Nov 27, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Qiagen N.V.

< Previous 1 2 3 4 5 6 Next >
QIAGEN Issues 2021 Sustainability Report
From QIAGEN N.V.
Via Business Wire
QIAGEN Launches Syndromic Test For QIAstat-Dx For Six Pathogens Similar To Monkeypox
Via Benzinga
QIAGEN Launches Syndromic Test for QIAstat-Dx Device to Combat Global Monkeypox Health Emergency
From QIAGEN N.V.
Via Business Wire
Qiagen Posts Robust Q2 Non-COVID Sales Growth, Lifts Annual Guidance
Qiagen N.V. (NYSE: QGEN) clocked Q2 FY22 revenues of $516 million, down 9% Y/Y, well above the consensus of $488.73 million. 
Via Benzinga
QIAGEN adds new biopharma products to QIAcuity digital PCR portfolio and launches Expert Custom Assay Design Service
From QIAGEN N.V.
Via Business Wire
Natera Clocks 28% Jump In Q1 Sales, Lifts FY22 Guidance
Via Benzinga
Qiagen Posts Upbeat Q1 Earnings, Raises FY22 Outlook
Via Benzinga
QIAGEN beats outlook for Q2 2022 and raises full-year 2022 outlook
From QIAGEN N.V.
Via Business Wire
QIAGEN’s Clinical Decision Support Platform QCI Surpasses Three Million NGS Patient Test Cases
From QIAGEN N.V.
Via Business Wire
QIAGEN N.V. to Release Results for Q2 2022 and Hold Webcast
From QIAGEN N.V.
Via Business Wire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Good morning, investor! We're back with a breakdown of the biggest pre-market stock movers for Tuesday to get the day started! 
Via InvestorPlace
U.S. CDC Endorses the Use of Digital PCR Technology for Wastewater Surveillance of Infectious Diseases – Including COVID-19 Outbreaks
From QIAGEN N.V.
Via Business Wire
QIAGEN’s Eco-Friendlier Products Earn Prestigious ACT Label
From QIAGEN N.V.
Via Business Wire
QIAGEN Expands Syndromic Testing Portfolio with the Launch of Higher-Capacity QIAstat-Dx Rise and Enhanced Panels
From QIAGEN N.V.
Via Business Wire
QIAGEN Acquires Majority Stake in Enzymes Provider BLIRT S.A.
From QIAGEN N.V.
Via Business Wire
QIAGEN Proposes Expansion of Supervisory Board
From QIAGEN N.V.
Via Business Wire
QIAGEN Adds HSV1/2 Herpes Assay With CE-IVD Certification for Use on NeuMoDx Integrated PCR System
From QIAGEN N.V.
Via Business Wire
QIAGEN exceeds outlook for Q1 2022, delivers strong 14% CER sales growth from non-COVID products and increases full-year outlook
From QIAGEN N.V.
Via Business Wire
Earnings Scheduled For April 27, 2022
Companies Reporting Before The Bell • Deutsche Bank (NYSE:DB) is projected to report earnings for its first quarter. 
Via Benzinga
QIAGEN N.V. to release results for Q1 2022 and hold Webcast
From QIAGEN N.V.
Via Business Wire
QIAGEN Reaches Milestone With 100 Million QuantiFERON Tests Used to Detect TB
From QIAGEN N.V.
Via Business Wire
QIAGEN Announces 20-F Annual Report Filing for 2021 Results
From QIAGEN N.V.
Via Business Wire
Death Cross Looms Over Qiagen Investors
If history is any guide, there may be trouble ahead for shares of Qiagen (NYSE:QGEN). A so-called "death cross" has formed on its chart and, not surprisingly, this could be... 
Via Benzinga
The Daily Biotech Pulse: Bristol-Myers Squibb Announces $5B Accelerated Buyback, Qiagen Reaps COVID Testing Windfall, WORLDSymposium Presentations Kick In
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Qiagen Q4 Earnings Beat Expectations On High Demand For COVID-19 Tests, Issues FY22 Guidance
Qiagen N.V. (NYSE: QGEN)  
Via Benzinga
Qiagen: Q4 Earnings Insights
Qiagen (NYSE:QGEN) reported its Q4 earnings results on Tuesday, February 8, 2022 at 04:05 PM. Here's what investors need to know about the announcement. Earnings Qiagen beat estimated earnings by... 
Via Benzinga
QIAGEN beats outlook for fourth quarter and full-year 2021, delivers 22% CER full-year sales growth from non-COVID products
From QIAGEN N.V.
Via Business Wire
The Daily Biotech Pulse: Pfizer, Amgen Shares Slip On Earnings, Editas Terminates Chief Medical Officer, Biogen Licenses Preclinical Rheumatoid Arthritis Biosimilar
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Qiagen's Earnings: A Preview
Qiagen (NYSE:QGEN) is set to give its latest quarterly earnings report on Tuesday, 2022-02-08. Here's what investors need to know before the announcement. Analysts estimate that Qiagen will likely... 
Via Benzinga
Earnings Scheduled For February 8, 2022
Companies Reporting Before The Bell • Pfizer (NYSE:PFE) is likely to report quarterly earnings at $0.87 per share on revenue of $24.20 billion. 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 LosAltos.com & California Media Partners, LLC. All rights reserved.